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L-Arginine depletion by arginase and 
polycations contributes to airway 
hyperresponsiveness after the          
late asthmatic reaction 
 
Harm Maarsingh, Bas E. Bossenga, I. Sophie T. Bos,             






Increased arginase activity and polycation-induced reduced cellular transport of L-
arginine are involved in airway hyperresponsiveness after the allergen-induced early 
asthmatic reaction, by attenuating L-arginine availability for nitric oxide (NO) 
production by constitutive NO synthase. Formation of peroxynitrite from superoxide 
anion and inducible NO synthase (iNOS)-derived NO is crucial for the development 
of airway hyperresponsiveness after the late asthmatic reaction. In the present 
study, we investigated the role of arginase and polycations in the development of 
airway hyperresponsiveness after the late asthmatic reaction. Using a guinea pig 
model of allergic asthma, we measured arginase activity in the airways and 
eosinophil peroxidase release by bronchoalveolar lavage cells, and examined the 
effects of the arginase inhibitor nor-NOHA and the polycation antagonist heparin on 
the responsiveness of isolated perfused tracheae to methacholine. Arginase activity 
and eosinophil peroxidase release were markedly increased after the late asthmatic 
reaction. This was associated with 2.0-fold airway hyperresponsiveness to 
methacholine. Nor-NOHA and heparin completely normalized  airway 
responsiveness, which was reversed by the NOS inhibitor L-NAME. Airway 
hyperresponsiveness was also reduced by exogenous L-arginine. A deficiency of 
bronchodilating NO in the airway wall, due to arginase- and polycation-induced 
attenuation of L-arginine, is involved in the development of airway 
hyperresponsiveness after the late asthmatic reaction. This could involve 
simultaneous production of NO and superoxide anion by iNOS at low L-arginine 
concentration, leading to a very efficient formation of the proinflammatory and 
procontractile nitrogen species peroxynitrite. Arginase inhibitors and polyanions may 
have therapeutic potential in allergic asthma. 
 
Introduction 
Allergic asthma is characterized by airway hyperresponsiveness (AHR) to non-
specific stimuli, which may be increased after acute allergic asthmatic reactions. 
Thus, in allergic asthmatics, as well as in sensitized guinea pigs, increased airway 
responsiveness to histamine and methacholine develops both after the early (EAR) 
and the late asthmatic reaction (LAR) [1,2]. 
 Nitric oxide (NO) is importantly involved in the regulation of airway tone. NO is 
produced by a family of NO synthase (NOS) isoforms that utilize the semi-essential 
amino acid L-arginine, oxygen and NADPH as substrates to produce NO and L-
citrulline. Three NOS isoforms have been identified: neuronal NOS (nNOS) and 
endothelial NOS (eNOS), which are constitutively expressed in inhibitory 
nonadrenergic noncholinergic (iNANC) nerves (nNOS), endothelial cells (eNOS) and 
epithelium (nNOS and eNOS) in the airway wall, and inducible NOS (iNOS), which is 
induced in the airway epithelium and inflammatory cells by proinflammatory 
cytokines during allergic airway inflammation [3]. Constitutive NOS (cNOS)-derived 
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NO is an important bronchodilator by causing relaxation of airway smooth muscle. In 
addition to its effect on airway smooth muscle tone, large amounts of NO produced 
by iNOS may have proinflammatory and cytotoxic effects [3,4]. 
 Recent studies have indicated that both under physiological and 
pathophysiological conditions NO production and airway responsiveness are under 
important control of L-arginine homeostasis [3,5,6]. L-Arginine is a semi-essential 
amino acid, which is taken up by the diet and which is endogenously produced from 
L-citrulline by the intestinal mucosa, as well as by some NO producing cells [6]. 
However, L-arginine requirements in most cells are met via uptake of L-arginine via 
specific cationic amino acid transporters [6,7]. Thus, the availability of L-arginine for 
NOS to produce NO in the airways is importantly regulated by cellular transport [8].  
 Substrate availability to NOS is also regulated by arginase, which hydrolyzes L-
arginine into L-ornithine and urea, and thus competes with NOS for the common 
substrate [5,6]. Although classically considered as an enzyme of the urea cycle, 
arginase also is also present in extrahepatic cells and tissues, including various cell 
types in the airways [5,6,8-14][Chapter 6]. The functional role of arginase in the 
airways has been established in isolated guinea pig tracheal preparations. Thus, 
constitutively present arginase activity attenuates both agonist-induced, epithelium-
derived [13] and iNANC nerve-mediated [14][Chapter 6] NO production, thereby 
enhancing the airway responsiveness to neural and nonneural stimuli. 
Using a guinea pig model of asthma, it has been shown that a deficiency of both 
neural and nonneural cNOS-derived NO importantly contributes to the development 
of AHR after the EAR [15,16][Chapter 7], which  is caused by reduced L-arginine 
availability to cNOS [16,17][Chapter 7]. At least two mechanisms are involved in this 
process. First, arginase activity in the airways is markedly increased after the EAR, 
leading to increased substrate competition with cNOS [16,18][Chapters 2&7]. 
Secondly, increased secretion of  (eosinophil-derived) polycations in the airways is 
involved [19][Chapter 3], presumably by inhibiting cellular transport of L-arginine into 
the airway epithelium [8,20]. A deficiency of cNOS-derived NO [21,22], increased 
expression of arginase [12] as well as release of eosinophil-derived polycations in 
the airways [23] have also been observed in patients with asthma, indicating that 
similar mechanisms may be operative in human pathophysiology. 
 During the allergen-induced LAR, iNOS is induced in human [24] as well as in 
guinea pig [4,25] airways. Significant correlations between exhaled (iNOS-derived) 
NO, AHR and airway eosinophilia have been observed in asthmatics, whereas all 
are reduced after glucocorticosteroid treatment [3,26-28]. Based on these 
observations, iNOS-derived NO is considered to be a marker of airway inflammation. 
Importantly, increased levels of exhaled NO also correlate with increased 
nitrotyrosine staining – a marker for peroxynitrite – in exhaled breath condensate of 
mild asthmatics [29]. In addition, increased nitrotyrosine staining in the airway 
epithelium and inflammatory cells in bronchial biopsies of asthmatic patients 




glucocorticosteroids decreased the observed nitrotyrosine staining in asthmatic 
patients [29,30]. These findings indicate that peroxynitrite, the reaction product of 
NO and superoxide anion, is importantly involved in iNOS-induced asthmatic airway 
inflammation and hyperresponsiveness.  
 In an in vivo guinea pig model for allergic asthma, we have previously 
demonstrated that iNOS may have both beneficial – by functional antagonism of 
histamine-induced bronchoconstriction - and detrimental - by promoting airway 
inflammation and epithelial damage - effects on allergen-induced AHR after the LAR 
[4]. In perfused guinea pig airways, the AHR after the LAR was reversed by the 
nonspecific NOS inhibitor Nω-nitro-L-arginine methyl ester (L-NAME) as well as by 
the superoxide anion scavenger superoxide dismutase, indicating that peroxynitrite 
is importantly involved in the development of AHR after the LAR [31].  
The role of L-arginine homeostasis in the production of peroxynitrite and 
development of AHR after the LAR is currently unknown. Therefore, in the present 
study, we examined the role of arginase, endogenous polycations and L-arginine 
availability in the development of AHR after the LAR, using perfused tracheal 
preparations obtained from ovalbumin-sensitized guinea pigs at 24 hours after 
ovalbumin-challenge. In addition, arginase activity was assessed in tracheal and 
bronchoalveolar lavage (BAL) cell homogenates, while  eosinophil activation was 
assessed in BAL cells. 
 
Methods 
Animals and sensitization 
Outbred specified pathogen free guinea pigs (Harlan, Heathfield, United Kingdom), 
weighing 700 – 900 g, were used in this study. Animals were actively IgE-sensitized 
to ovalbumin using aluminum hydroxide as an adjuvant as described by Van 
Amsterdam et al [32] and used experimentally 4 to 8 weeks after sensitization. All 
protocols described in this study were approved by the University of Groningen 
Committee for Animal Experimentation. 
 
Allergen provocation 
Ovalbumin challenges were performed by inhalation of aerosolized solutions in a 
specially designed provocation cage, in which the guinea-pigs could move freely 
[33]. Provocations were performed by inhalation of an aerosol concentration of 0.5 
mg/ml ovalbumin in saline and were discontinued when the first signs of respiratory 
distress were observed. The guinea pigs were sacrificed 24 hours after ovalbumin 









Tracheae were mounted in a perfusion setup as described previously [15], and 
placed in a organ bath (37°C) containing 20 ml of gassed Krebs-Henseleit medium 
(the serosal or extraluminal (EL) compartment). The lumen was perfused with 
recirculating Krebs-Henseleit solution from a separate 20 ml bath (mucosal or 
intraluminal (IL) compartment) at constant flow (12 ml/min). Hydrostatic pressure 
was measured at the distal and proximal ends of the trachealis and the difference 
between the two pressures (∆P), which reflects the resistance of the tracheal 
segment to perfusion and is a function of the diameter of the airway, was recorded.  
After equilibration, 1 µM isoproterenol was added to the EL compartment for maximal 
smooth muscle relaxation to assess basal tone. After washout, the trachea was 
extraluminally exposed to 40 mM KCl to obtain a receptor-independent reference 
response and washed again until basal tone was reached. Subsequently, a 
cumulative concentration response curve was made with intraluminally administered 
methacholine. When used, the specific arginase inhibitor Nω-hydroxy-nor-L-arginine 
(nor-NOHA; 5.0 µM) and L-NAME (1.0 mM) were applied to the IL reservoir, while 
heparin (from porcine intestinal mucosa; 250 units/ml) was applied to both the IL and 
EL reservoir; all 40 minutes prior to agonist-addition. L-Arginine (5.0 mM) was 
applied to the EL reservoir 30 minutes prior to agonist-addition. 
 
Bronchoalveolar lavage  
Animals were anaesthetized and the lungs were gently lavaged with saline via a 
tracheal canula. After centrifugation (200g; 10 minutes, 4°C), BAL cells were 
resuspended to a final volume of 1.0 ml in PBS and total cell numbers were 
determined. For cytological examination, cytospin-preparations were stained with 
May-Grünwald and Giemsa and a differential cell count was performed.  
 
Arginase assay 
Tracheal homogenates were prepared as described  previously [18][Chapter 2]. BAL 
cells were homogenized in 1.0 ml 20 mM Tris-HCl, 2 µM phenylmethylsulphonyl 
fluoride (PMSF), pH 7.4 using a polytron homogenizer (Kinematica GmbH, Luzern, 
Switzerland). The homogenate was centrifuged at 20,000g for 30 minutes at 4°C 
and the supernatant was used for the assessment of arginase activity. Arginase 
activity was determined by measuring the conversion of L-[guanidino-14C]arginine to 
[14C]urea, using a modified protocol as described by Custot et al. [34]. In short, 
homogenate aliquots (50 µl) were incubated in a final volume of 150 µl, containing 
25 mM Tris-HCl, 0.67 mM MnCl2, 1.66 mM L-arginine and 1 µl of L-[guanido-
14C]arginine (51.5 mCi/mmol), pH 7.4 for 20 minutes at 37°C. Reactions were 
terminated by adding 450 µl of ice-cold stop buffer, containing 7 M urea, 0.25 M 
acetic acid, 10 mM L-arginine, pH 3.6. Samples were applied to vials containing 400 




centrifuged at 750 g for 1 minute and the resulting supernatants were centrifuged 
again at 750 g for 1 minute. Final supernatants (150 µl) were counted in triplicate in 
4 ml Ultima Gold scintillation fluid using a Beckman LS 1701 liquid scintillation 
counter. The specificity of the assay in measuring arginase activity was confirmed by 
the inhibitory effect of nor-NOHA [18][Chapter 2]. 
 
Eosinophil peroxidase assay 
BAL cells were centrifuged and resuspended in Hanks balanced salt solution to a 
final density of 2.5 ×106 cells/ml and incubated for 30 minutes at 37 oC. Cell 
incubation was stopped by placing the samples on ice, followed by immediate 
centrifugation and subsequent decantation of the supernatant for measurement of 
eosinophil peroxidase (EPO) activity. The cells were lysed, centrifuged and the 
supernatant was collected to measure the remaining intracellular EPO content. The 
EPO activity was analysed according to the kinetic assay described by White et al 
[35], which is based on the oxidation of O-phenylenediamine by EPO in the 
presence of hydrogen peroxide. 
 
Data analysis 
IL responses of the tracheal tube preparations to methacholine were expressed as a 
percentage of the response induced by EL administration of 40 mM KCl. The 
contractile effect of 10 mM methacholine (highest concentration) was defined as Emax 
[15]. Using this Emax, the sensitivity to methacholine was evaluated as pEC50  (-log 
EC50) value. Arginase activity was expressed as pmol urea produced per mg protein 
per minute. EPO activity was expressed as a percent of total amount of EPO 
(amount of EPO in the supernatant of stimulated cells + the amount present in the 
supernatant of the lysed cells).   
 Results are expressed as means ± SEM. Statistical analysis was performed 
using the Student's t-test for unpaired observations. Differences were considered 
statistically significant at P<0.05. 
 
Materials 
Ovalbumin (grade III), aluminum hydroxide, (-)-isoprenaline hydrochloride, heparin 
sodium salt from porcine intestinal mucosa (grade IA), Nω-nitro-L-arginine methyl 
ester, L-arginine hydrochloride, phenylmethylsulphonyl fluoride, O-phenylenediamine 
dihydrochloride and May-Grünwald and Giemsa stain were obtained from Sigma 
Chemical Co. (St. Louis, MO, USA), methacholine chloride from Aldrich (Milwaukee, 
WI, USA) and Hanks balanced salt solution from Gibco Life Technologies (Praisley, 
Schotland). L-[guanido-14C] arginine (specific activity 51.5 mCi/mmol) was obtained 
from New England Nuclear Life Science Products, Inc (Boston, MA, U.S.A.). Nω-
hydroxy-nor-L-arginine was kindly provided by Dr J.-L. Boucher (Université Paris V, 
Paris, France). 
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Arginase activity was significantly increased after the allergen-induced LAR, both in 
tracheal homogenates (1.9-fold, P<0.05) and in homogenates of BAL cells (2.9-fold, 

















The total cell number as well as the numbers of eosinophils and neutrophils in the 
BAL were significantly increased 24 hours after ovalbumin challenge (Figure 2A). 
BAL eosinophils were activated after challenge, as indicated by increased 

















Figure 2: Total and differential cell count (A) and EPO release from BAL eosinophils (B) 
obtained from unchallenged and ovalbumin (OA) challenged guinea pigs. EPO release is 
expressed as % of total cellular EPO content and 100 % represents 19.3 ± 3.9 and 10.4 ± 1.3 
ng/ml EPO/106 cells for unchallenged and OA challenged animals, respectively. Results are 
means ± SEM of 4-8 experiments. *P<0.05 and ***P<0.001 compared to control. 
Figure 1: 
Arginase activity in tracheal and 
BAL cells homogenates from 
unchallenged and ovalbumin 
(OA)-challenged guinea pigs. 
Results are means ± SEM of 4-8 



























Consistent with our previous study [31], a 2.0-fold increase in Emax to IL 
methacholine was observed in perfused tracheal preparations obtained from 
ovalbumin-challenged guinea pigs after the LAR as compared to unchallenged 
controls (P<0.005), without an effect on the sensitivity (pEC50) to the agonist (Figure 
3; Table I). Remarkably, in tracheae from ovalbumin-challenged guinea pigs, 
incubation with L-arginine (5.0 mM) caused a partial, but significant, decrease in 
airway responsiveness to methacholine by 70% (P<0.05), without an effect on the 


















Incubation of the preparations from ovalbumin-challenged animals with nor-NOHA 
(5.0 µM; IL) completely normalized the AHR to methacholine to the level of 
unchallenged controls (P<0.001), whereas no effect on the sensitivity was observed 
(Figure 4A; Table I). Similar to nor-NOHA, incubation with heparin (250 U/ml; IL & 
EL) also normalized the AHR (P<0.001; Figure 4B; Table I). The normalized 
responsiveness both in the presence of nor-NOHA and in the presence of heparin 
was completely reversed to the level of untreated ovalbumin-challenged airways 
after coincubation with L-NAME (1.0 mM; IL; P<0.001 both; Figures 4A&B; Table I). 
In line with previous studies [13,18,19][Chapters 2&3], L-NAME, nor-NOHA, heparin 
and L-arginine had no effect on basal airway tone (not shown). 
 
 
Figure 3: Methacholine (MCh)-
induced constriction of intact 
perfused tracheae from 
unchallenged and ovalbumin (OA)-
challenged guinea pigs, in the 
absence and presence of 5.0 mM 
L-arginine. Results are means ± 
SEM of 6-8 experiments. 
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Figure 4: Methacholine (MCh)-induced constriction of intact perfused tracheae from 
unchallenged and ovalbumin (OA)-challenged guinea pigs, in the absence and presence of 
(A) 5.0 µM nor-NOHA or (B) 250 U/ml heparin alone or in combination with 1.0 mM l-NAME. 
Results are means ± SEM of 4-9 experiments. 
 
TABLE I. Effects of nor-NOHA and heparin, in the absence and presence of L-
NAME, and L-arginine on the responsiveness to intraluminally administered 
methacholine of intact perfused tracheae from ovalbumin-challenged guinea pigs. 
 Emax pEC50 n 
 (% KCl) (-log M)  
Unchallenged control 51.6 ± 1.2 3.12 ± 0.20 6 
Ovalbumin-challenged         105.1 ± 10.8* 3.28 ± 0.13 8 
     + 5.0 µM nor-NOHA           52.8 ± 5.2††† 3.41 ± 0.15 8 
          + 1.0 mM L-NAME         104.8 ± 11.1‡ 3.48 ± 0.16 4 
     + 250 U/ml heparin           54.2 ± 11.0 †† 2.84 ± 0.19 6 
          + 1.0 mM L-NAME         108.9 ± 6.5 § 3.25 ± 0.08 4 
     +  5.0 mM L-arginine           67.6 ± 11.0† 3.16 ± 0.15 8 
*P<0.005 compared with unchallenged control; †P<0.05, ††P<0.01 and ††P<0.001 
compared with ovalbumin-challenged control; ‡P<0.001 compared with nor-
NOHA; §P<0.01 compared with heparin 
 
Discussion 
The present study demonstrates for the first time that a deficiency of bronchodilating 
NO, due to L-arginine limitation caused by increased arginase activity and 




 Using a guinea pig model of acute allergic asthma, we have previously 
demonstrated that both NO and superoxide are involved the development of AHR 
after the LAR, presumably by the formation of peroxynitrite [31]. Thus, incubation 
with L-NAME as well as superoxide dismutase fully reversed the AHR after the LAR 
in perfused tracheal preparations [31]. Remarkably, we now demonstrated that 
incubation with L-arginine, as a precursor of NO, did not worsen but significantly 
decreased the AHR after the LAR. A relationship between L-arginine availability to 
iNOS and peroxynitrite generation has been described by Xia et al [36,37]. Thus, in 
macrophages it was demonstrated that, particularly at low L-arginine concentrations, 
iNOS may produce both NO by the oxygenase moiety of the enzyme and superoxide 
anion by its reductase moiety, leading to a highly efficient formation of peroxynitrite 
[36,37]. Increasing the concentration of L-arginine promotes the NO production, 
while the generation of superoxide anion, and hence peroxynitrite, is reduced [37]. 
Therefore, allergen-induced limitation of L-arginine to iNOS caused by increased 
arginase activity and polycations may be involved in the development of AHR after 
the LAR by promoting the generation of peroxynitrite. Notably, a role for arginase 
and L-arginine limitation in the superoxide anion production by NOS has also been 
indicated in activated cultured cerebellar granule  neurons  [38], tumor-bearing 
mouse-derived immature myeloid cells [39] and preeclamptic villi [40]. 
 It has been well established that most, if not all of the deleterious effects induced 
by iNOS-derived NO in the airways may proceed via increased formation of 
peroxynitrite [30,41,42]. Increased generation of peroxynitrite has been indicated by 
enhanced 3-nitrotyrosine immunostaining in the airways of allergen-challenged 
guinea pigs and of asthmatic patients [30,43]. In asthmatics, increased nitrotyrosine 
staining was observed in the airway epithelium and inflammatory cells, which 
correlated with iNOS expression, AHR and airway inflammation [30], and in exhaled 
breath condensate, which correlated with levels of exhaled NO [29].  Peroxynitrite is 
procontractile and proinflammatory [30,31,44] and is known to induce degranulation 
of eosinophils, epithelial damage and AHR [41,42] as well as airway microvascular 
hyperpermeability [43] in guinea pigs. Taken together, it can be postulated that not 
iNOS-derived NO itself but rather the reaction with (iNOS-derived) superoxide anion 
to peroxynitrite may importantly account for the detrimental effects of increased 
iNOS expression after the LAR. In addition, increased scavenging of NO by 
superoxide anion also contributes to AHR by causing a deficiency of free 
bronchodilating NO.  
 That iNOS-derived NO may have beneficial effects on airway responsiveness 
was nicely demonstrated in a study by Hjoberg et al using iNOS overexpressing 
mice [45]. As in asthmatics, levels of exhaled NO are increased in these iNOS 
overexpressing mice as compared to wild type. Interestingly, iNOS-derived NO per 
se had no proinflammatory effects in the lung and even decreased airway 
responsiveness to methacholine [45]. In our in vivo guinea pig model of allergic 
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asthma, we demonstrated that iNOS-derived NO - apart from promoting 
inflammation and epithelial damage – also had a beneficial effect on allergen-
induced AHR after the LAR by partially reducing airway responsiveness to histamine 
due to its bronchodilating effect [4]. Therefore, the detrimental effect of iNOS-derived 
NO may be primed by its molecular environment, causing the formation of 
peroxynitrite. Apart from iNOS, superoxide is also produced by activated 
macrophages, eosinophils and neutrophils [46]. The probability to form peroxynitrite 
is greater when NO and superoxide are generated within close reach [47]. 
Therefore, iNOS-derived superoxide may be the most effective source for NO to 
form peroxynitrite. Accordingly, iNOS expression and nitrotyrosine staining were 
closely colocalized in bronchial biopsies of asthmatics [30].  
 One mechanism underlying L-arginine limitation after the LAR is increased 
arginase activity in the airways. Increased arginase activity was found in tracheal 
homogenates as well as in BAL cells, indicating that inflammatory cells may be 
involved. Interestingly, the AHR after the LAR was completely normalized after 
incubation with the specific arginase inhibitor nor-NOHA, showing a prominent role 
for arginase in the development of L-arginine limitation and AHR. Coincubation with 
L-NAME completely reversed the decrease in AHR by nor-NOHA, indicating that 
arginase inhibition results in stimulation of bronchodilating NO production. 
Previously, we have demonstrated that arginase activity in the airways is already 
increased after the EAR, contributing to AHR after this reaction by causing a 
deficiency of both neural and agonist-induced nonneural NO, presumably by limiting 
the availability of L-arginine to cNOS [16,18][Chapters 2&7]. Thus, L-arginine 
limitation due to increased arginase activity is importantly involved in the 
development of AHR both after the EAR and the LAR.  
 In two mouse models of allergic asthma, induced by sensitization with ovalbumin 
or Aspergillus fumigatus, it was confirmed that pulmonary arginase activity is 
increased after allergen challenge [12]. By microarray analysis of gene expression, 
this finding was extended by the observation that genes related to L-arginine 
metabolism, including the cytosolic isoform arginase I, and the mitochondrial isoform 
arginase II, belonged to the most prominently overexpressed genes [12]. Lung 
arginase activity and mRNA expression of both arginase I and II were strongly 
induced by the Th2 cytokines IL-4 and IL-13, known to be involved in allergic airway 
inflammation [12]. Similar observations were also done in cultured rat airway 
fibroblasts [11].  
 According to our observations, arginase has been observed in inflammatory 
cells, especially in (alveolar) macrophages and neutrophils [10,48,49]. Moreover, 
Th2 cytokines are able to increase arginase activity in macrophages but not in 
neutrophils [49,50]. Differential BAL cell counts in the present study demonstrate 
that while the number of  macrophages is not affected by allergen challenge, the 
number of neutrophils is increased after the LAR. However, since 




remains unclear whether the increased arginase activity in the BAL cells is due to 
increased induction of arginase in macrophages, an increased number of neutrophils, 
or both.  
 Recently, it has been demonstrated that protein expression of arginase I is 
increased in BAL cells of asthmatic patients [12]. In addition, enhanced mRNA 
expression of arginase I was observed in the airway epithelium and in inflammatory 
cells in bronchial biopsies of these patients [12], indicating that arginase is also 
involved in the pathophysiology of human asthma. Surprisingly, a relationship 
between increased serum arginase activity and decreased plasma levels of L-
arginine has been observed in asthmatic patients during exacerbation [51]. 
A second important mechanism regulating intracellular L-arginine availability to NOS 
is the uptake by transporters of the y+ system. Using the polyanion heparin, we 
previously demonstrated that endogenous polycations contribute to the NO 
deficiency and AHR after the EAR, presumably by inhibiting cellular L-arginine 
uptake [19][Chapter 3]. Indeed, polycations, like major basic protein and its analogue 
poly-L-arginine are known to inhibit L-arginine uptake [8] and cause AHR [20,52-54] 
by affecting airway epithelial function [54] and inducing NO deficiency [20]. In 
addition, pretreatment with heparin inhibits allergen-induced AHR in guinea pigs 
[53]. Interestingly, we now demonstrated that heparin also completely normalized 
the AHR after the LAR, indicating that endogenous polycations are involved in this 
process as well. Similar to nor-NOHA, the effect of heparin was reversed by L-
NAME, indicating that heparin normalizes the AHR by stimulating the production of 
bronchodilating NO. The similar effects of arginase inhibition and polycation 
scavenging on AHR suggest a common pathway which could rely on an increased 
effectiveness of arginase under conditions of polycation-induced substrate limitation.  
 In line with our hypothesis, we demonstrated that the number of eosinophils in 
the BAL was  markedly increased after allergen challenge and that eosinophil 
activation was increased as well, as indicated by enhanced release of EPO by these 
cells. The observation of increased EPO release corresponds to our previous finding 
of increased EPO activity in the BAL fluid at 24 hours after ovalbumin challenge, 
which correlated with AHR in vivo [55]. 
 In conclusion, a deficiency of bronchodilating NO in the airway wall, due to 
arginase- and polycation-induced attenuation of L-arginine, is involved in the 
development of AHR after the allergen-induced LAR. This process may involve 
simultaneous production of NO and superoxide anion by iNOS at the low L-arginine 
concentration, leading to a very efficient formation of the proinflammatory and 
procontractile nitrogen species peroxynitrite, which may similarly be involved in the 
development of AHR (Figure 5). Therefore, arginase inhibitors and polycation 
antagonists may have therapeutic potential in allergic asthma. 
 
 






























Figure 5: Postulated role of L-arginine homeostasis in the development of AHR after the LAR. 
Increased arginase activity induced by Th2 cytokines as well as increased release of 
eosinophil-derived polycations result in a decreased availability of L-arginine to iNOS, which is 
induced during the LAR. The reduced availability of L-arginine to iNOS promotes the 
production of both NO and superoxide anion (O2-) by the enzyme. NO and O2- rapidly react to 
form the highly reactive nitrogen species peroxynitrite (ONOO-), which has procontractile and 
proinflammatory actions in the airways and contributes to the allergen-induced AHR. 
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